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Background: Marijuana use is prevalent among patients with cocaine dependence and
often non-exclusionary in clinical trials of potential cocaine medications. The dual-focus
of this study was to (1) examine the moderating effect of baseline marijuana use on
response to treatment with levodopa/carbidopa for cocaine dependence; and (2) apply
an informative-priors, Bayesian approach for estimating the probability of a subgroup-
by-treatment interaction effect. Method: A secondary data analysis of two previously
published, double-blind, randomized controlled trials provided complete data for the histor-
ical (Study 1: N =64 placebo), and current (Study 2: N =113) data sets. Negative binomial
regression evaluated Treatment Effectiveness Scores (TES) as a function of medication
condition (levodopa/carbidopa, placebo), baseline marijuana use (days in past 30), and their
interaction.Results:Bayesian analysis indicated that therewas a 96% chance that baseline
marijuana use predicts differential response to treatment with levodopa/carbidopa. Simple
effects indicated that among participants receiving levodopa/carbidopa the probability that
baselinemarijuana confers harm in terms of reducingTESwas 0.981; whereas the probabil-
ity that marijuana confers harmwithin the placebo conditionwas 0.163. For every additional
day of marijuana use reported at baseline, participants in the levodopa/carbidopa condition
demonstrated a 5.4% decrease inTES; while participants in the placebo condition demon-
strated a 4.9% increase inTES.Conclusion:The potentialmoderating effect ofmarijuana on
cocaine treatment response should be considered in future trial designs. Applying Bayesian
subgroup analysis proved informative in characterizing this patient-treatment interaction
effect.
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INTRODUCTION
Multiple substance use is common in cocaine patients, making
it a challenge to obtain samples of “pure” or singly dependent
subjects for clinical trials research. The response has been to
broaden the eligible subject pool by allowing concurrent use or
abuse of other substances, although recent articles have debated
the degree of acceptable heterogeneity for pharmacotherapy effi-
cacy research (O’Brien and Lynch, 2003; Rounsaville et al., 2003).
Moreover, when patients who use multiple drugs are included in a
cocaine clinical trial, the investigation needs to take into account
this increased variability. Not all clinical trials have consistently
reported the impact of concomitant substance use on response to
cocaine treatment.
Marijuana use is especially prevalent among patients with
cocaine dependence (Miller et al., 1990a,b; Aharonovich et al.,
2005, 2006). In an earlier report our research group described
some interesting characteristics associated with marijuana-using
individuals presenting for medication treatment trials (Lindsay
et al., 2009). Among the large percentage (46.4%) of concurrent
marijuana users seeking treatment for cocaine dependence, those
who used marijuana frequently (i.e., 10 or more days over the past
30) showed a profile of greater clinical impairment, exemplified
by more severe addiction severity scores, and heavier patterns of
drug use, than those who used marijuana occasionally or not at
all.
The extent to which marijuana-using cocaine-dependent
patients fare worse in treatment compared to their non-marijuana-
using counterparts is unclear. Aharonovich et al. (2006) examined
the impact of continued cannabis use during methylphenidate
treatment of comorbid cocaine dependence and ADHD and found
that moderate or intermittent use of cannabis was associated with
better retention in treatment than heavy use or abstinence. The
effect of cannabis use on cocaine abstinence rates was not signif-
icant, contrary to previous findings (Aharonovich et al., 2005).
Other studies have failed to find an effect of marijuana use on
retention or cocaine treatment outcomes (Budney et al., 1996;
Higgins et al., 2003). In a recent retrospective analysis of data
from three clinical trials of contingency management, Alessi et al.
www.frontiersin.org October 2012 | Volume 3 | Article 92 | 1
Green et al. Bayesian analysis in cocaine treatment
(2011) found that pretreatment marijuana use did not dampen
the benefit of this behavioral treatment in reducing cocaine use.
In sum, the small literature shows mixed results on the impact
of cannabis use on cocaine treatment outcome, underscoring the
need to better understand this potential interaction, especially as it
relates to the development of effective medications for treatment
of cocaine dependence.
The prognostic significance of baseline marijuana use on treat-
ment outcome is the focus of the present study. Having reported
positive results from earlier trials of levodopa pharmacotherapy
for cocaine dependence (Mooney et al., 2007; Schmitz et al., 2008),
we carried out a secondary analysis to determine whether levodopa
treatment effects varied as a function of marijuana use at baseline.
Observations by Lindsay et al. (2009) led us to expect that mar-
ijuana use would moderate the effect of levodopa by reducing
overall treatment effectiveness. Specifically, we hypothesized that
within the subgroup of cocaine subjects having high levels of base-
line marijuana use, treatment with levodopa pharmacotherapy
would be less effective.
The second aim of this study is to demonstrate a more
appropriate, statistical method for conducting secondary analysis
of subgroup treatment effects. Analytically, evaluation of sub-
group effects entails testing the interaction of treatment and
some baseline, subgroup measurement. A large literature has
criticized the use of traditional, Frequentist approaches as inad-
equate due to their often low power, and dichotomous evalua-
tion of the evidence (i.e., significance testing; Dixon and Simon,
1991; Simon et al., 1996; Simon and Freedman, 1997; Simon,
2002; Green et al., 2009). For instance, Brookes et al. (2001)
showed that a trial with 80% power to detect a main effect of
treatment possessed only 29% power to detect an interaction
effect as large as the main effect. Positing an interaction effect
matching the magnitude of a main effect reflects an extremely
optimistic scenario. Stated another way, if the interaction was
as large as the anticipated main effect, the sample size would
still require quadrupling in order to maintain 80% power to
detect the interaction. The same literature, criticizing conven-
tional Frequentist methods for analyzing treatment-by-subgroup
interaction effects, has recommended Bayesian methods as an
alternative.
Bayesian analytical methods avoid issues of reduced power and
significance testing by evaluating the probability that the alterna-
tive (HA) hypothesis exists, given the observed data, and any prior
evidence for HA. These probabilities can be meaningfully refined,
unlike p values that cannot, by using informative prior probability
distributions (for more extensive review of the limitations of p
values, and the advantages of Bayesian statistical approaches see
Dixon and Simon, 1991; Schervish, 1996; Goodman, 1999, 2005;
Berry, 2006). Thus, the researcher is able to attach a probability
value to the parameter of interest, in this case, the interaction effect,
e.g.,“given the observed data, the probability that an interaction of
at least magnitude X exists is Y.” The Bayesian approach provides
a natural analysis for the present situation, in which we sought to
incorporate information from a previous study to improve pre-
cision in estimating the interaction parameter. Referred to as the
Bayesian power prior approach, this paper demonstrates how to
pool historical data from an earlier randomized clinical trial with
current data, and produce more precise conclusions regarding
the hypothesis of interest, i.e., that heterogeneity in response to
treatment is a function of baseline marijuana use.
MATERIALS AND METHODS
SAMPLE
The present study analyzed data obtained from two completed
levodopa trials for cocaine dependence. In Study 1, cocaine-
dependent subjects enrolled in a 9-week, randomized, double-
blind, placebo-controlled trial comparing placebo to 400/100 mg
and 800/200 mg levodopa/carbidopa in a sustained-release prepa-
ration (Sinemet CR). In Study 2, cocaine-dependent subjects
received levodopa/carbidopa (800/200 mg) or placebo delivered
in combination with behavioral therapy interventions of varying
intensity. Study 1 established the safety, tolerability, and feasi-
bility of levodopa therapy in cocaine outpatients, while Study 2
demonstrated support for use of levodopa pharmacotherapy with
behavioral contingency management. Details of each trial design,
sample composition, and main findings are presented elsewhere
(Mooney et al., 2007; Schmitz et al., 2008). The samples used here
are subsets of the overall trial data, selected due to their com-
parability in dosing for levodopa (800/200 mg), and behavioral
intervention (cognitive-behavioral therapy without contingency
management). To demonstrate the proposed Bayesian analysis,
Study 1 (N = 64 complete observations) formed the historical
dataset and Study 2 (N = 113 complete observations) provided
the current dataset.
All participants provided written informed consent. The Com-
mittee for the Protection of Human Subjects (CPHS) of the Uni-
versity of Texas Medical School, Houston reviewed and approved
the research, consent, and all study materials.
MEASURES
Moderator variable
Baseline level of marijuana use was defined according to self-
reported number of days of use over the past 30 using the
Addiction Severity Index (ASI; McLellan et al., 1980). In addition
to self-reported marijuana use, urine specimens were screened
for ∆-9-THC, the primary active metabolite of marijuana. The
concordance rate between self-report and urinalysis testing was
acceptable (76%).
Treatment response variable
The Treatment Effectiveness Score (TES; Ling et al., 1997) was
used as an outcome indicator of treatment response. The TES is
calculated by assigning one point for each cocaine-negative urine
sample (cutoff< 300 ng/ml), and no points for positive or miss-
ing samples. Both studies required three urine samples per week.
Studies 1 and 2 were 9 and 12 weeks respectively permitting TES
values that ranged from 0–27 to 0–36 negative urines.
ANALYSIS
Bayesian statistical reasoning
Frequentist and Bayesian statistical reasoning comprise the prin-
cipal modes of statistical reasoning, taking distinct but symbi-
otic approaches to uncertainty/probability. Frequentist reasoning
defines probability as the frequency of an event in the limit of
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a series of infinite, repeated trials. Often illustrated using a large
number of repeated coin flips, counting the number of heads, or
tails, long run frequency counts provide an estimate of the fixed
parameter that is governs the performance of the coin. Bayesian
reasoning defines probability as a judgment regarding the likeli-
hood of an event (Hájek, 2003). Often referred to as a subjective or
personalist probability, Bayesian reasoning is best operationalized
in terms of the proportion of a fixed amount of money an observer
would bet on a specific outcome (Hájek, 2003). Statistically, the
Frequentist approach models the data as random, and the para-
meter as fixed and unknown. In contrast the Bayesian approach
models a parameter as unknown and random, and the observed
data as fixed (Lucke, 2004). Frequentist reasoning indirectly evalu-
ates the alternative hypothesis (HA) by rejecting or failing to reject
the null hypothesis (H0). This permits statements such as “given
that the null hypothesis is true, the probability of observing data
this extreme or more extreme is Z.” Indirect evaluation of the HA
by testing H0 means that no probability valuation is attached to
directly to possible values of HA. While Frequentist Confidence
Intervals represent an attempt at providing an index of HA they
are properly interpreted as those interval which have a 95% chance
of capturing the true parameter estimate and say nothing about
the differential plausibility of the values they include. They can-
not, because in Frequentist statistics the true parameter estimate
is fixed (i.e., it has a probability of one): while the true parame-
ter is fixed, the confidence interval moves with each new sample.
Bayesian reasoning, defines the governing parameter of interest
(in this case the interaction coefficient) as random, and there-
fore permits probability statements regarding what the value of
that parameter might be. The product of a Bayesian analysis is
the posterior distribution, which indicates the differential prob-
ability that the parameter of interest takes various values. Since
the relative probability of various values being the true parameter
within this interval is defined by the shape of the posterior dis-
tribution, it is possible to comment on the probability that HA
takes on some value or range of values. This means that, given the
observed data and a formally articulated prior distribution repre-
senting the anticipated value and uncertainty for the parameter of
interest, Bayesian modeling permits direct quantification of evi-
dence for the alternative hypothesis (HA). The Bayesian approach
permits statements such as “given the observed data, the prob-
ability that an interaction of at least magnitude X exists is Y.”
Under certain conditions (e.g., vague priors) the values of the
estimates from Bayesian and Frequentist methods are often quite
similar, however their interpretation is quite different: Bayesian
inference directly addresses the alternative hypothesis, while Fre-
quentist inference does so indirectly by rejecting or failing to reject
the null hypothesis. In making this distinction the current paper is
not arguing that one approach is inherently correct and the other
not. Rather, we agree with Kendall (1949) that each of these dif-
ferent notions of probability ultimately cannot stand without the
other. More recently, Wijeysundera et al. (2009) pointing out that
the approaches answer different albeit complementary, questions.
Bayesian posterior probabilities
In this paper we present a Bayesian analyses as an alternative
approach to assessing the association between baseline marijuana
use and treatment effectiveness. In brief, Bayesian reasoning holds
that inferences about a hypothesis should be encapsulated in a
probability distribution, given the observed data. This distribu-
tion, known as the posterior probability distribution, summarizes
evidence for the parameter value as the product of previous evi-
dence (prior distribution), and any newly gathered data. Bayes’
Theorem (Eq. 1) expresses this relation:
p (θ|data) = p (data|θ) p (θ)
p (data)
(1)
where p(data|θ) is the likelihood and p(θ) is the prior distribution.
The denominator p(data) functions as a scaling coefficient and is
often omitted from the equation to give:
p (θ|data) ∝ p (data|θ) p (θ) (2)
Specifically, the probability that the parameter takes on some value
(or range of values) is proportional to the product of the observed
data (i.e., likelihood) and prior evidence. Stated in prose, this reads,
“The probability (i.e., “p”) of the parameter value θ given (i.e., “|”)
the data is proportional to (i.e., “∝”) the probability of the data
given the parameter value θ [i.e., “p(data| θ)”] multiplied by the
prior probability of θ [i.e., “p(θ)”].
Bayesian prior distributions
The prior distribution is a mathematical formalization of existing
evidence for a parameter value before observing new data (Gill,
2002). In the absence of historical evidence, the prior distribu-
tion is based on subjective judgment, representing varying degrees
of skepticism regarding the pre-existing evidence (i.e., enthusi-
astic, neutral, or skeptical). When access to data from previous
studies is available, it is scientifically reasonable and statistically
advantageous to incorporate this historical information into the
prior distribution. However this requires investigators to evaluate
the comparability or exchangeability of the historical and current
data. Ibrahim and Chen advocate the use of power priors (Chen
et al., 2000; Ibrahim and Chen, 2000; Ibrahim et al., 2003; Chen and
Ibrahim, 2006) to produce posterior distributions that incorporate
historical data sets. Implementation of such methods permits the
evaluation of the sensitivity of posterior estimates to assumptions
regarding the comparability of the constituent samples. Assuming
that such comparability exists, combining the information exist-
ing in more than one sample may have the benefit of improving
the precision of the resulting estimates.
Bayesian power priors
Study 1 provided the existing, historical data set (D0 of size n0) and
Study 2 provided the current data set (D1 of size n1). We assumed
an initial prior distribution (i.e., before observing D0) represented
by p(θ). Incorporation of D0 into the estimation of the posterior
distribution based on D1 takes the following form:
p (θ|D1) ∝ p (D1|θ) p(D0|θ)a0 p (θ) (3)
Where p(D0|θ)a0 p(θ) represents the power prior which incorpo-
rates the historical data from D0, raised to the power a0 which
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is restricted to 0≤ a0≤ 1, and the initial prior [i.e., p(θ)]. Con-
ceptually, values of a0 range from a0= 0, in which D0 is fully
discounted or excluded from the model, to a0= 1 in which D0
carries the same weight as D1. In essence a0 provides a means of
regulating the amount of information that D0 contributes to the
analysis of D1. Two reasons for adjusting the weight of the histor-
ical data are: (1) discounting very large historical data sets so that
they do not overwhelm the information in a smaller, more cur-
rent data set, and (2) accounting for inter-sample heterogeneity
which may result from differences in the experimental proto-
col, sampling, etc. (Chen and Ibrahim, 2006; De Santis, 2006).
While empirical estimation of a0 from the data might reflect a
weighting that minimizes the loss of information across the two
samples (Ibrahim et al., 2003; Chen and Ibrahim, 2006) such
an approach is problematic (Neuenschwander et al., 2009), lead-
ing to extremely low estimates of a0 even for identical data sets
(Neelon and O’Malley, 2010). Moreover, an attempt to remedy
this (Duan et al., 2005) leads to improved but low estimates of
a0 (Neelon and O’Malley, 2010). We adopt a “conditional power
priors” (Neelon and O’Malley, 2010, p. 2) approach, following
Spiegelhalter et al. (2004) and evaluating the full range of values
for a0 to understand the degree to which discounting the his-
torical data influences inferences based on the resulting posterior
distribution.
Model specification
Negative binomial regression evaluated TES as a function of
treatment condition (levodopa/carbidopa, placebo), baseline mar-
ijuana use (number of days in the past 30), and their interaction.
Unlike Poisson regression, negative binomial regression accounts
for over-dispersion in the count data characterizing both the
historical and current data sets. Following Eq. 3, initial prior dis-
tributions [i.e., p(θ)] took the form ∼Normal (0, var= 1× 106)
for regression coefficients (i.e., normally distributed with a mean
of zero and a variance of 1,000,000; the prior is centered on the
null hypothesis and expresses substantial uncertainty). While SAS
9.3 specifies a ∼Gamma(0.001, 0.001) prior as a default for the
dispersion term (Gamma functions describe a family of distri-
bution on the positive real number line. The parameters values
0.001 and 0.001 refer to as the α and β parameters respectively.
These two quantities capture the shape (i.e., α) and rate (i.e., β)
of the specified distribution. The inverse of the rate (i.e., 1/β)
is called the scale parameter. The two parameters convey the
shape and the spread or dispersion of the distribution. In, perhaps
more familiar terms, the mean of a Gamma distributed variable
is α/β while its variance is α/β2). There has been some concern
that such priors may not be appropriate (see Gelman, 2006 for
a discussion in the context of normal distributed data). As such
we follow DiPrete et al. (2011) as well as Zheng et al. (2006).
Reasoning that the dispersion parameter might take values rang-
ing (0–∞), these authors specify a ∼Uniform (0,1) prior on the
inverse of the dispersion coefficient [a ∼Uniform (0,1) distrib-
ution spans the range zero through one with all values having
an equal probability of occurring (i.e., it is a straight line)]. SAS
v. 9.3 code for doing so is relatively straightforward and avail-
able from the corresponding author. These vague, neutral prior
distributions acknowledge a relative state of ignorance regarding
parameter values prior to observing either the historical or cur-
rent data sets. Again, following Eq. 3, the likelihood incorporating
the historical data (i.e., p(D0|θ)a0 ) required specification of the
term a0. Following Spiegelhalter et al. (2004) we evaluated use
of the historical data at values ranging from a0= 0 to a0= 1.
Estimates of parameter values for the interaction term are the
appropriate indices for evaluating heterogeneity in response to
treatment as a function of baseline marijuana use. As in Pois-
son regression, exponentiated parameter estimates and intervals
correspond to risk ratios (R.R.) and Credible Intervals (C.B.I.)
respectively.
Computational software
Analyses utilized Proc Markov Chain Monte Carlo (MCMC; SAS
v. 9.3; SAS Institute Inc, 2010) which provides a flexible computing
environment for the MCMC simulations for estimating Bayesian
posterior distributions. An example applying Proc MCMC to a
relatively straightforward use of power priors in estimating a bino-
mial proportion using historical and current data is provided in
SAS Documentation (SAS Institute Inc, 2011). Examples of statis-
tical code and salient output for the current analysis are available
from the corresponding author.
RESULTS
Baseline marijuana use characteristics of pharmacotherapy groups
from their respective studies are provided in Table 1.
Table 2 displays Bayesian estimates for a0= 0 and a0= 1 as
well as frequentist estimates of the interaction term. Estimates
of the interaction coefficient for a0= 0 and a0= 1 and a0= 1
are R.R.= 0.887 (95% C.B.I. 0.781–1.022) and R.R.= 0.899 (95%
C.B.I. 0.808–1.016) respectively. That is, relative to patients in the
placebo condition, participants receiving levodopa demonstrated
a decrease in TES by a factor of 0.887 (i.e., 11.3%) or 0.899 (i.e.,
10.1%) for the two most extreme weights that might be attached
to the historical evidence (i.e., a0= 0 and a0= 1 respectively).
Note that the point estimates are quite similar and that the 95%
Credible Interval for a0= 0 entirely contains the corresponding
interval for a0= 1. The broader credible interval for a0= 0 which
encompass the interval for a0= 1 reflects the decrease in uncer-
tainty that occurs as the historical data receives greater weight
in the analysis; a reasonable result given that inclusion of more
information from the historical data permits greater precision in
the resulting estimates. Inspection of Figures 1 and 2 show that,
at different levels of a0, the value of the parameter estimate for
the interaction, as well as the probability that increased baseline
Table 1 | Baseline marijuana use levels.
Variable Placebo l-DOPA
Mean, SD (N ) Mean, SD (N )
HISTORICAL DATA
Baseline marijuana use (days in past 30) 3.41, 7.68 (29) 1.97, 5.67 (35)
Baseline marijuana use (years of use) 9.17, 10.06 (29) 11.03, 9.96 (34)
CURRENT DATA
Baseline marijuana use (days in past 30) 3.28, 7.23 (58) 3.24, 6.94 (55)
Baseline marijuana use (years of use) 13.43, 10.71 (58) 10.55, 9.21 (55)
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Table 2 | Exponentiated parameter estimates and 95% credible intervals for a0=0 and a0=1.
Risk ratio 95% Credible limits
95% Lower limit 95% Upper limit
NEGATIVE BINOMIAL REGRESSION FORTES
a0=0
Intercept 3.158 1.895 5.694
Medication 3.346 1.483 7.650
Marijuana 1.062 1.000 1.160
Medication*marijuana 0.887 0.781 1.022
Dispersion 28.566 11.451 107.651
a0=1
Intercept 3.376 2.184 5.552
Medication 2.376 1.217 4.646
Marijuana 1.050 0.999 1.124
Medication*marijuana 0.899 0.808 1.016
Dispersion 38.695 16.805 118.570
FREQUENTIST MAXIMUM LIKELIHOOD ESTIMATES FORTHE INTERACTION OF MEDICATION AND MARIJUANA
Sample Risk ratio estimate 95% Confidence interval Likelihood ratio statistic
Historical sample 0.856 0.687–1.066 χ(1)=1.77, p<0.184
Current sample 0.887 0.787–1.001 χ(1)=3.12, p<0.078
Combined samples 0.899 0.810–0.998 χ(1)=3.30, p<0.069
FIGURE 1 | Estimates of the parameter for the interaction term (i.e., theta) as a function of different values of a0.
marijuana use predicts decreased TES scores in the levodopa con-
dition, remains relatively constant. Inspection of Figure 3 shows
the magnitude of the decrease in the Credible Interval range and
the variance of the posterior distribution as a percentage of its
width at a0= 0, as a function of altering a0. In the current case,
the range of the Credible Interval decreases by approximately
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FIGURE 2 | Estimates of the probability that increased baseline marijuana use predicts decreasedTES scores in the levodopa treatment as a function
of a0.
FIGURE 3 | Change in the precision of the parameter estimate as a
function of a0.The red line shows the magnitude of the decrease in the
Credible Interval range as a percentage of its width at a0 =0, as a
function of altering a0. The blue line shows the magnitude of the
decrease in the variance of the posterior distribution as a function of
altering a0.
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FIGURE 4 | Posterior distributions of the interaction parameter at values of a0 =0, 0.5, and 1.0.
14% while the variance of the posterior distribution of the expo-
nentiated coefficient decreases by almost 26%. Finally, Figure 4
shows the posterior distributions of the parameter value for the
interaction coefficient. The distributions, displayed for a0= 0, 0.5,
and 1.0, appear to be quite similar. Given the failure to demon-
strate that alterations in a0 result in substantial changes to the
estimated value of the interaction coefficient, coupled with the
increase in precision for the estimate, it is reasonable to give
the historical data a weight comparable to the current data (i.e.,
a0= 1).
From a substantive perspective, using a0= 1, the probability
that baseline marijuana use predicts differential response to treat-
ment with levodopa/carbidopa is 0.96 (i.e., where θ is less than
or equal to a R.R. of 1.0; Figure 4). Based on the Frequentist
Likelihood Ratio Test statistics presented in Table 1, neither the
historical, current nor the combined data sets lead to rejection of
the null hypothesis.
Inspecting the simple effects of baseline marijuana use indicates
that among participants receiving levodopa/carbidopa the proba-
bility that baseline marijuana confers harm in terms of treatment
outcome is 0.981 (Figure 5). The probability that marijuana con-
fers harm within the placebo condition is 0.163 (Figure 5). For
every additional day of marijuana use reported at baseline, partic-
ipants in the levodopa/carbidopa condition demonstrate a 5.4%
decrease in TES (R.R. 0.946, 95% C.B.I. 0.864–1.069; Figure 6).
For every additional day of marijuana use reported at baseline,
participants in the placebo condition demonstrate a 4.9% increase
in TES (R.R. 1.049, 95% C.B.I. 1.002–1.115; Figure 6).
DISCUSSION
Subgroup analyses are informative for characterizing heterogene-
ity in response to treatment for cocaine dependence. Inadequate
power minimizes the usefulness of conventional, Frequentist tests
of the salient interaction terms. As such Bayesian methods pro-
vide a more appropriate, probabilistic measure of the evidence for
subgroup effects. Improved precision for estimates of subgroup
effects can result from incorporation of historical data into the
analysis of a current data set. Doing so raises questions regarding
the comparability of the data sets, and the weight subsequently
accorded the historical data. Power priors offer a mechanism for
formalizing the degree to which historical data is incorporated into
the analysis of a newer data set.
In the current context this type of analysis points, with high
probability, to the existence of a subgroup effect of baseline
marijuana use on response to treatment for cocaine dependence
with levodopa/carbidopa. Specifically, higher marijuana use pre-
dicted lower treatment effectiveness (cocaine-negative urines)
in the levodopa/carbidopa condition, but not in the placebo
condition. It is possible that higher marijuana use at baseline
operates as a proxy for cocaine severity that has been shown
to distinguish subpopulations in terms of treatment response.
Repeating our analysis with baseline cocaine use as a covari-
ate, however, failed to alter any substantive conclusions. To the
extent that frequent marijuana use at baseline continued during
treatment, this pattern of concomitant use may have influenced
levodopa’s efficacy via providing competing drug reinforcement,
perhaps counteracting the putative dopamine-restoring effects
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FIGURE 5 |TES as a function of baseline marijuana and treatment condition.
FIGURE 6 | Posterior densities for the simple effect of baseline marijuana use within each condition.
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of levodopa. Although generally a well-tolerated medication in
cocaine-dependent patients, levodopa may interact with mari-
juana to produce less tolerable effects and thus reduce com-
pliance and efficacy. Based on these findings, future research
should examine how marijuana use during treatment inter-
acts with cocaine use in moderating the effects of levodopa
treatment: (i) chronic marijuana use may produce changes in
cannabinoid-1 and/or dopamine receptor availability which may
alter the effects of levodopa in cocaine-dependent subjects;
(ii) intoxication following acute marijuana use may alter the
probability of concurrent cocaine use in the levodopa condi-
tion relative to placebo via drug–drug interactions not yet fully
understood.
Limitations of the current study include the post hoc/secondary
nature of the data analysis. A large literature has discussed the
problem of post hoc subgroup analyses (Adams, 1998; Assmann
et al., 2000; Pocock et al., 2002; Cook et al., 2004; Rothwell, 2005).
The clear danger is that post hoc selection of subgroups for analysis
may result in capitalization on chance variability in the data. While
this is somewhat mitigated by the finding that the interaction
remains consistent, pooling across the two samples, it is still pos-
sible that idiosyncrasies in recruitment, or secular trends in the
population from which sampling occurred resulted in biased esti-
mates of the interaction effect. Prospective confirmation of these
findings have broad implications for analyzing patient heterogene-
ity in response to treatment, the design of clinical trials to account
for population heterogeneity through stratified randomization, as
well as more specific implications for the potential usefulness of
levodopa pharmacotherapy in treatment cocaine dependence.
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